ABBV AbbVie Inc

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: global biopharmaceutical company focused on innovative therapies in immunology, neuroscience, oncology, aesthetics, and eye care
• • New emphasis: expanded indications and geographic approvals for Skyrizi and Rinvoq across autoimmune diseases, plus new oncology ADC Epkinly approved for lymphoma
• • Strategic shift: single global business segment operating model aligned for unified resource allocation and long-term strategic goal achievement
• • Quantitative highlight: 2025 gross revenues in U.S. distributed mostly through three wholesalers, none exceeding 43% share
• • Noteworthy fact: continued biosimilar competition pressure on Humira globally, with evolving FDA regulatory pathway and complex approval process

Risk Factors

• • FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
• • Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules
• • Capital investment including new U.S. API facility in Illinois and biologics expansion in Massachusetts increases operational complexity and execution risk
• • Biosimilar competition driving Humira U.S. net revenues down 57% in 2025 threatens market position and revenue stability
• • $6.5B contingent consideration liabilities fair value increase in 2025 linked to Skyrizi sales projections creating significant financial risk exposure

Management Discussion & Analysis

• • Revenue $61.2B, up 9% YoY on reported and constant currency basis
• • Operating earnings $15.1B, operating margin approximately 24.7% (15.1B/61.2B)
• • Best segment: not explicitly broken down; costs include $7.4B amortization, $6.5B contingent liabilities fair value change
• • Cash flow from operations $19.0B, no disclosed buybacks or dividends, ongoing investment in pipeline and brands
• • Forward outlook: $100B pledged for US R&D/capex over decade, tariff exemption for 3 years, risk of revenue erosion from Medicare price controls starting 2026

What are the latest ABBV SEC filings in 2026?

AbbVie Inc (ABBV) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on May 8, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ABBV file its most recent 10-K annual report?

AbbVie Inc (ABBV) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ABBV 10-Q quarterly reports?

AbbVie Inc (ABBV)'s most recent 10-Q quarterly report was filed on May 8, 2026. SignalX displays every ABBV 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ABBV filed recently?

AbbVie Inc (ABBV)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ABBV insider trading activity (Form 4)?

SignalX aggregates every ABBV Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ABBV file with the SEC?

AbbVie Inc (ABBV) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ABBV filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for AbbVie Inc (ABBV).

What is ABBV's SEC CIK number?

AbbVie Inc (ABBV)'s SEC CIK (Central Index Key) number is 1551152. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1551152 to look up all ABBV filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ABBV return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from AbbVie Inc (ABBV) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.